51
Participants
Start Date
July 31, 2012
Primary Completion Date
April 30, 2015
Study Completion Date
August 31, 2015
ganetespib
Ganetespib 150 mg/m2 will be administered intravenously, twice weekly, for three consecutive weeks of each 4 week cycle.
Synta Pharmaceuticals Investigative Site, Wilrijk
Synta Pharmaceutical Investigative Site, Charleroi
Synta Pharmaceuticals Investigative Site, New York
Synta Pharmaceuticals Investigative Site, Durham
Synta Pharmaceuticals Investigative Site, Altanta
Synta Pharmaceuticals Investigative Site, Birmingham
Synta Pharmaceuticals Investigative Site, Columbus
Synta Pharmaceutical Investigative Site, Houston
Synta Pharmaceuticals Investigative Site, Boston
Synta Pharmaceuticals Investigative Site, Philadelphia
Synta Pharmaceuticals Investigative Site, Córdoba
Synta Pharmaceuticals Investigative Site, Lima
Synta Pharmaceutical Investigative Site, Seoul
Synta Pharmaceuticals Investigative Site, Seoul
Synta Pharmacuetical Investigative Site, Seoul
Synta Pharmaceuticals Investigative Site, Seoul
Synta Pharmaceuticals Investigative Site, Rosario Santa Fe
Synta Pharmaceuticals Investigative Site, Brussels
Synta Pharmaceuticals Investigative Site, São Paulo
Synta Pharmaceuticals Investigative Site, Barcelona
Synta Pharmaceutical Investigative Site, Edinburgh
Synta Pharmaceutical Investigative Site, Glasgow
Synta Pharmaceutical Investigative Site, Nottingham
Synta Pharmaceuticals Investigative Site, Oxford
Synta Pharmaceutical Investigative Site, Peterborough
Synta Pharmaceuticals Corp.
INDUSTRY